|
CA2915124C
(en)
|
2001-11-13 |
2018-08-14 |
The Trustees Of The University Of Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
ES2602352T3
(es)
|
2001-12-17 |
2017-02-20 |
The Trustees Of The University Of Pennsylvania |
Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
EP2298926A1
(en)
*
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
WO2006078279A2
(en)
|
2004-04-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
|
US9592284B2
(en)
|
2004-04-28 |
2017-03-14 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost
|
|
EP2357010B1
(en)
|
2005-04-07 |
2013-06-12 |
The Trustees of The University of Pennsylvania |
Method of increasing the function of an AAV vector
|
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
|
EP2009990B1
(en)
|
2006-04-07 |
2016-09-21 |
The Board of Regents of The University of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
|
US20090317417A1
(en)
*
|
2006-04-28 |
2009-12-24 |
The Trustees Of The University Of Pennsylvania |
Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
ES2634118T3
(es)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Vectores de virus modificados y métodos para fabricar y utilizar los mismos
|
|
HUE044522T2
(hu)
|
2009-04-30 |
2019-10-28 |
Univ Pennsylvania |
Adeno-asszociált vírus konstrukciókat tartalmazó légúti vezetõ sejtek célzására szolgáló kompozíciók
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2010141706A1
(en)
*
|
2009-06-03 |
2010-12-09 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
|
SG10201502270TA
(en)
|
2010-03-29 |
2015-05-28 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP3514232A1
(en)
|
2010-04-23 |
2019-07-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のａａｖベースの治療
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
CN107828820B
(zh)
*
|
2010-10-27 |
2022-06-07 |
学校法人自治医科大学 |
用于向神经系统细胞导入基因的腺相关病毒粒子
|
|
EP4234571A3
(en)
*
|
2011-02-10 |
2023-09-27 |
The University of North Carolina at Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
JP6224459B2
(ja)
|
2011-02-17 |
2017-11-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
|
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
RS66184B1
(sr)
|
2011-04-22 |
2024-12-31 |
Univ California |
Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
|
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
ES2857773T5
(es)
*
|
2011-08-24 |
2024-06-04 |
Univ Leland Stanford Junior |
Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
|
WO2013082268A1
(en)
|
2011-11-30 |
2013-06-06 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming
|
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
|
US9611305B2
(en)
|
2012-01-06 |
2017-04-04 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
US20130280170A1
(en)
|
2012-04-20 |
2013-10-24 |
Aladar A. Szalay |
Imaging methods for oncolytic virus therapy
|
|
EP2847337A4
(en)
*
|
2012-05-09 |
2016-04-27 |
Univ Oregon Health & Science |
ADENO ASSOCIATED VIRUS PLASMIDS AND VECTORS
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
CA2878171C
(en)
|
2012-07-11 |
2021-04-27 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
|
|
EP3769789A1
(en)
|
2012-08-01 |
2021-01-27 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
JP6387350B2
(ja)
|
2012-09-28 |
2018-09-05 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
希突起神経膠細胞を標的とするアデノ随伴ウイルスベクター
|
|
WO2014055960A1
(en)
|
2012-10-05 |
2014-04-10 |
Genelux Corporation |
Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
EP2970946A4
(en)
*
|
2013-03-13 |
2016-09-07 |
Philadelphia Children Hospital |
ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
|
|
EP2970884A4
(en)
|
2013-03-14 |
2016-11-02 |
Univ Florida |
DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS
|
|
CA2904396A1
(en)
*
|
2013-03-15 |
2014-09-18 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav vectors
|
|
EP3747998B1
(en)
|
2013-03-15 |
2024-07-24 |
The Trustees of the University of Pennsylvania |
Compositions for treating mpsi
|
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
|
ES2897508T3
(es)
|
2013-05-31 |
2022-03-01 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
JP6985795B2
(ja)
|
2013-09-26 |
2021-12-22 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
標的遺伝子治療のための合成コンビナトリアルａａｖカプシドライブラリー
|
|
EP3054995A1
(en)
*
|
2013-10-07 |
2016-08-17 |
Kiromic, LLC |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
|
JP6552511B2
(ja)
*
|
2013-10-11 |
2019-07-31 |
マサチューセッツ アイ アンド イヤー インファーマリー |
祖先ウイルス配列を予測する方法およびその使用
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
RS60902B1
(sr)
|
2014-03-09 |
2020-11-30 |
Univ Pennsylvania |
Kompozicije korisne u lečenju nedostatka ornitinske transkarbamilaze (otc)
|
|
PL3117005T3
(pl)
|
2014-03-10 |
2024-11-04 |
Uniqure Ip B.V. |
Dodatkowo ulepszone wektory aav produkowane w komórkach owadzich
|
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
|
WO2015164778A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennysylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
SG11201609207SA
(en)
|
2014-05-13 |
2016-12-29 |
Univ Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
|
EP3800260A1
(en)
|
2014-09-24 |
2021-04-07 |
City of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3207130B1
(en)
|
2014-10-14 |
2019-08-07 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
WO2016073739A1
(en)
*
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
|
CN107106689A
(zh)
*
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
|
KR102584655B1
(ko)
|
2014-11-14 |
2023-10-06 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
RU2727015C2
(ru)
*
|
2014-11-21 |
2020-07-17 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Векторы aav, нацеленные на центральную нервную систему
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
JP6754361B2
(ja)
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
ES2900973T3
(es)
|
2015-01-07 |
2022-03-21 |
UNIV AUTòNOMA DE BARCELONA |
Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
|
|
AU2016206518B2
(en)
|
2015-01-16 |
2020-03-05 |
University Of Washington |
Novel micro-dystrophins and related methods of use
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
KR20170137730A
(ko)
|
2015-03-02 |
2017-12-13 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
|
|
AU2016229000B2
(en)
|
2015-03-10 |
2021-11-04 |
The Trustees Of Columbia University In The City Of New York |
Recombinant Glut1 adeno-associated viral vector constructs and related methods for restoring Glut1 expression
|
|
EP3277819B1
(en)
*
|
2015-03-24 |
2021-03-03 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
WO2016176191A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
EP3291765A4
(en)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
METHOD FOR THE DELIVERY OF AN ACTIVE SUBSTANCE TO THE EYE
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
CA2985786A1
(en)
*
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
|
CN108135994B
(zh)
|
2015-05-13 |
2022-01-25 |
宾夕法尼亚州大学信托人 |
Aav-介导的抗-流感抗体的表达及其使用方法
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
WO2016196324A1
(en)
|
2015-05-29 |
2016-12-08 |
University Of Floridia Research Foundation, Inc. |
Methods for diagnosing huntington's disease
|
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
LT3872085T
(lt)
*
|
2015-07-30 |
2023-05-10 |
Massachusetts Eye & Ear Infirmary |
Viruso prototipo sekos ir jų panaudojimas
|
|
GB2557123B
(en)
|
2015-07-31 |
2021-11-03 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
EP3332012A4
(en)
|
2015-08-06 |
2019-01-16 |
The Trustees of The University of Pennsylvania |
GLP-1 AND USE THEREOF IN COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES
|
|
JP6905755B2
(ja)
|
2015-08-25 |
2021-07-21 |
デューク ユニバーシティ |
Ｒｎａガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
|
|
US11117942B2
(en)
|
2015-08-31 |
2021-09-14 |
The Trustees Of The University Of Pennsylvania |
AAV-EPO for treating companion animals
|
|
RU2727411C2
(ru)
|
2015-09-24 |
2020-07-21 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиция и способ для лечения заболевания, опосредованного комплементом
|
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
WO2017066764A2
(en)
*
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US12188037B2
(en)
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
CA3002982A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
|
WO2017075119A1
(en)
|
2015-10-28 |
2017-05-04 |
The Trustees Of The Univeresity Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
CN108348621A
(zh)
|
2015-11-05 |
2018-07-31 |
竹治疗股份有限公司 |
用于基因治疗的经修饰的弗里德赖希共济失调基因及载体
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
EP3400304B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
WO2017100704A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
JP6990182B2
(ja)
|
2015-12-11 |
2022-02-15 |
マサチューセッツ アイ アンド イヤー インファーマリー |
蝸牛および前庭細胞に核酸を送達するための材料および方法
|
|
JP7082050B2
(ja)
*
|
2015-12-14 |
2022-06-07 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脊髄性筋萎縮症の処置において有用なアデノ－関連ウイルスベクター
|
|
EP3389724B1
(en)
|
2015-12-14 |
2020-07-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
US11241506B2
(en)
|
2015-12-14 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
US10973929B2
(en)
|
2016-02-03 |
2021-04-13 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type I
|
|
IL300254B2
(en)
|
2016-02-05 |
2025-06-01 |
Univ Emory |
Administration of single stranded or self-complementary adeno-associated virus 9 by injection into the cerebrospinal fluid to target gene therapy to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2017180915A2
(en)
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
AU2017248659B2
(en)
|
2016-04-15 |
2022-08-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating hemophilia A
|
|
WO2017181113A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
CN109661470A
(zh)
|
2016-04-15 |
2019-04-19 |
宾夕法尼亚州大学信托人 |
新型aav8突变衣壳和含有其的组合物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
MA44873A
(fr)
|
2016-04-15 |
2019-03-13 |
Univ Pennsylvania |
Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
|
|
WO2017184463A1
(en)
|
2016-04-17 |
2017-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
AU2017261249B2
(en)
*
|
2016-05-03 |
2021-05-06 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
|
CN109476707B
(zh)
|
2016-05-13 |
2022-12-02 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
|
AU2017268382B2
(en)
|
2016-05-18 |
2023-09-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
RU2758488C2
(ru)
|
2016-05-18 |
2021-10-28 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
|
JP2019517274A
(ja)
|
2016-06-13 |
2019-06-24 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ |
最適化されたｃｌｎ１遺伝子および発現カセットおよびそれらの使用
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
EP3481958A4
(en)
|
2016-07-08 |
2019-12-25 |
The Trustees of The University of Pennsylvania |
METHOD AND COMPOSITIONS FOR TREATING DISTURBANCES AND DISEASES WITH RDH12
|
|
EP3487523B1
(en)
|
2016-07-19 |
2023-09-06 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
IL263801B2
(en)
|
2016-07-26 |
2024-01-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
JP7071332B2
(ja)
|
2016-07-29 |
2022-05-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異カプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
|
|
IL264872B2
(en)
|
2016-08-18 |
2025-02-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
US10457940B2
(en)
*
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
EP3548065B1
(en)
|
2016-12-01 |
2022-11-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
WO2018126112A1
(en)
|
2016-12-30 |
2018-07-05 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating phenylketonuria
|
|
MX2019007873A
(es)
|
2016-12-30 |
2019-11-18 |
Univ Pennsylvania |
Terapia génica para tratar la enfermedad de wilson.
|
|
WO2018134168A1
(en)
|
2017-01-17 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
|
EP3576760A2
(en)
|
2017-02-01 |
2019-12-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
|
AU2018219895C1
(en)
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
CA3114549A1
(en)
|
2017-02-21 |
2018-08-30 |
University Of Florida Research Foundation, Incorporated |
Modified aav capsid proteins and uses thereof
|
|
WO2018154096A1
(en)
|
2017-02-24 |
2018-08-30 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
US11827906B2
(en)
*
|
2017-02-28 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clade f vector and uses therefor
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
SG11201907611WA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
|
CN119752819A
(zh)
|
2017-03-01 |
2025-04-04 |
宾夕法尼亚州立大学托管会 |
用于眼部病症的基因疗法
|
|
EP3589311A1
(en)
|
2017-03-02 |
2020-01-08 |
Genethon |
Method for removing anti-aav antibodies from a blood-derived composition
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
CN110809581A
(zh)
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
|
CA3056249A1
(en)
|
2017-03-24 |
2018-09-27 |
Lankenau Institute For Medical Research |
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
|
CN110770344B
(zh)
|
2017-03-31 |
2024-09-17 |
北京三诺佳邑生物技术有限责任公司 |
shRNA表达框、携带其的多核苷酸序列及其应用
|
|
EP3610016A1
(en)
|
2017-04-10 |
2020-02-19 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
WO2018191666A1
(en)
|
2017-04-14 |
2018-10-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
|
JP7526455B2
(ja)
*
|
2017-04-17 |
2024-08-01 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節
|
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
AU2018261790B2
(en)
|
2017-05-05 |
2024-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
|
WO2018204803A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
JP7327803B2
(ja)
|
2017-05-09 |
2023-08-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症（ａｌｓ）を処置する方法
|
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質（ａａｐ）依存性を改変する方法および組成物
|
|
RU2019139555A
(ru)
|
2017-05-11 |
2021-06-11 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия нейрональных цероидных липофусцинозов
|
|
WO2018218359A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
EP3638316A4
(en)
|
2017-06-14 |
2021-03-24 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY FOR EYE DISEASES
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019006418A2
(en)
*
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US20200121746A1
(en)
|
2017-06-30 |
2020-04-23 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
JP2020526514A
(ja)
|
2017-07-06 |
2020-08-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉ型を治療するための遺伝子治療
|
|
FI3648783T3
(fi)
|
2017-07-07 |
2024-09-10 |
Genethon |
Uudet polynukleotidit, jotka koodaavat ihmisen FKRP-proteiinia
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
BR112020001060A2
(pt)
|
2017-07-27 |
2020-07-14 |
Novartis Ag |
variantes de trem2 resistentes a shedase
|
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US11680249B2
(en)
|
2017-08-28 |
2023-06-20 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
FI3684423T3
(fi)
|
2017-09-20 |
2023-06-15 |
4D Molecular Therapeutics Inc |
Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
TWI835747B
(zh)
|
2017-09-22 |
2024-03-21 |
賓州大學委員會 |
用於治療黏多醣病 ii 型之基因治療
|
|
JP7350337B2
(ja)
|
2017-09-26 |
2023-09-26 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
MX2020004540A
(es)
|
2017-10-18 |
2020-08-03 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
|
|
AU2018350992A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
|
WO2019077159A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
|
|
AU2018372235B9
(en)
|
2017-11-27 |
2022-03-10 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
JP7389744B2
(ja)
|
2017-11-30 |
2023-11-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉａ型のための遺伝子療法
|
|
CA3083761A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iiib
|
|
JP2021506861A
(ja)
|
2017-12-19 |
2021-02-22 |
アコーオス インコーポレイテッド |
内耳への治療用抗体のａａｖ媒介送達
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019143803A1
(en)
|
2018-01-17 |
2019-07-25 |
Adrenas Therapeutics, Inc. |
Adeno-associated virus gene therapy for 21-hydroxylase deficiency
|
|
BR112020015798A2
(pt)
|
2018-02-01 |
2021-03-09 |
Homology Medicines, Inc. |
Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
EP3758724A4
(en)
*
|
2018-02-27 |
2022-07-06 |
The Trustees of The University of Pennsylvania |
NOVEL VECTORS OF ADENO-ASSOCIATED VIRUS (AAV), AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
|
MX2020008932A
(es)
|
2018-02-27 |
2020-10-01 |
Univ Pennsylvania |
Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
|
|
EP3765624A4
(en)
*
|
2018-03-16 |
2022-05-25 |
Research Institute at Nationwide Children's Hospital |
Increasing tissue specific gene delivery by capsid modification
|
|
WO2019195449A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
EP3773743A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
EP3775266A4
(en)
|
2018-04-05 |
2021-06-30 |
Massachusetts Eye and Ear Infirmary |
METHOD OF MANUFACTURING AND USING COMBINATIONAL BAR-CODED NUCLEIC ACID LIBRARIES WITH DEFINED VARIATION
|
|
WO2019193119A1
(en)
|
2018-04-05 |
2019-10-10 |
Genethon |
HYBRID RECOMBINANT ADENO-ASSOCIATED VIRUS SEROTYPE BETWEEN AAV9 AND AAVrh74 WITH REDUCED LIVER TROPISM
|
|
EP3780952A4
(en)
|
2018-04-16 |
2022-03-09 |
The Trustees of the University of Pennsylvania |
COMPOSITIONS AND METHODS OF TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
|
AU2019255745A1
(en)
|
2018-04-18 |
2020-11-19 |
The Trustees Of Columbia University In The City Of New York |
Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
|
|
BR112020021903A2
(pt)
|
2018-04-27 |
2021-03-02 |
Rocket Pharmaceuticals, Ltd. |
terapia genética para degeneração do snc
|
|
CA3098566A1
(en)
|
2018-04-29 |
2019-11-07 |
Zhuchun WU |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
EP3787771A1
(en)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Scalable clarification process for recombinant aav production
|
|
KR102877876B1
(ko)
|
2018-05-08 |
2025-10-28 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
|
WO2019217513A2
(en)
|
2018-05-09 |
2019-11-14 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
CN112368391A
(zh)
|
2018-05-11 |
2021-02-12 |
马萨诸塞眼科耳科诊所 |
腺相关病毒的肝脏特异性嗜性
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
EP3813845A4
(en)
|
2018-05-15 |
2022-10-26 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
MX2020012077A
(es)
|
2018-05-15 |
2021-03-09 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
ES2966045T3
(es)
|
2018-06-04 |
2024-04-18 |
Calidi Biotherapeutics Inc |
Vehículos basados en células para la potenciación de la terapia viral
|
|
EP3802829A4
(en)
|
2018-06-08 |
2022-10-19 |
University of Massachusetts |
ANTISENSE OLIGONUCLEOTIDES TO RESTORE DYSFERLIN PROTEIN EXPRESSION IN CELLS FROM PATIENTS WITH DYSFERLINOPATHY
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
WO2019241535A2
(en)
|
2018-06-14 |
2019-12-19 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant aav production
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
CA3106010A1
(en)
|
2018-07-12 |
2020-01-16 |
Rocket Pharmaceuticals, Ltd. |
Gene therapy vectors for treatment of danon disease
|
|
WO2020016655A2
(en)
|
2018-07-17 |
2020-01-23 |
Helixmith Co., Ltd. |
Treatment of neuropathy with dna constructs expressing igf-1 isoforms
|
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
KR20210043580A
(ko)
|
2018-08-10 |
2021-04-21 |
리젠엑스바이오 인크. |
재조합 aav 생산을 위한 규모 조정 가능한 방법
|
|
WO2020037303A1
(en)
|
2018-08-16 |
2020-02-20 |
The Regents Of The University Of California |
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
|
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
AU2019333315B2
(en)
|
2018-08-30 |
2022-09-29 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ASCL1
|
|
KR20210084459A
(ko)
|
2018-09-26 |
2021-07-07 |
캘리포니아 인스티튜트 오브 테크놀로지 |
표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
JP7289033B2
(ja)
|
2018-10-01 |
2023-06-09 |
徹 宮崎 |
神経変性疾患治療剤
|
|
KR20210071017A
(ko)
|
2018-10-01 |
2021-06-15 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Gm1 강글리오시드증 치료에 유용한 조성물
|
|
CN112955557A
(zh)
|
2018-10-01 |
2021-06-11 |
奥特吉尼克斯制药公司 |
用于治疗丙酸血症的基因疗法
|
|
AU2019354995B2
(en)
|
2018-10-02 |
2024-12-12 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
EP3861113A1
(en)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
EP3861107A1
(en)
*
|
2018-10-05 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
|
|
EP3867412A1
(en)
|
2018-10-15 |
2021-08-25 |
REGENXBIO Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
|
MX2021004602A
(es)
|
2018-10-22 |
2021-09-08 |
Univ Rochester |
Edición del genoma por inserción no homóloga de adn dirigida utilizando una proteína de fusión retroviral integrasacas9.
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
AU2019377141B2
(en)
|
2018-11-06 |
2024-06-06 |
Calidi Biotherapeutics (Nevada), Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
|
BR112021009481A2
(pt)
|
2018-11-16 |
2021-08-17 |
Astellas Pharma Inc. |
método para tratamento da distrofia muscular direcionando gene de utrofina.
|
|
CN113891934A
(zh)
|
2018-11-21 |
2022-01-04 |
因达普塔治疗公司 |
扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
|
|
BR112021009739A2
(pt)
*
|
2018-11-30 |
2021-10-19 |
Novartis Ag |
Vetores virais aav e usos dos mesmos
|
|
CN113727998A
(zh)
|
2018-11-30 |
2021-11-30 |
高山免疫科学股份有限公司 |
Cd86变体免疫调节蛋白及其用途
|
|
JP7590968B2
(ja)
|
2018-12-05 |
2024-11-27 |
アビオナ・セラピュ―ティクス・インコーポレイテッド |
遺伝子送達のための組み換えアデノ随伴ウイルスベクター
|
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
WO2020142653A1
(en)
|
2019-01-04 |
2020-07-09 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy constructs for treating wilson disease
|
|
JP7416451B2
(ja)
|
2019-01-14 |
2024-01-17 |
ユニバーシティ オブ ロチェスター |
ＣＲＩＳＰＲ－Ｃａｓによる標的化された核内ＲＮＡ切断及びポリアデニル化
|
|
CN113631225A
(zh)
|
2019-01-18 |
2021-11-09 |
沃雅戈治疗公司 |
用于生产aav颗粒的方法和系统
|
|
US20230193315A1
(en)
|
2019-01-31 |
2023-06-22 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
|
EP3927381A1
(en)
|
2019-02-22 |
2021-12-29 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
WO2020174368A1
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
MX2021010266A
(es)
|
2019-02-26 |
2021-09-23 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de la enfermedad de krabbe.
|
|
CA3176660A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
CA3130196A1
(en)
|
2019-03-25 |
2020-10-01 |
Isabelle Richard |
Production of large-sized quasidystrophins using overlapping aav vectors
|
|
SG11202110607WA
(en)
|
2019-04-01 |
2021-10-28 |
Tenaya Therapeutics Inc |
Adeno-associated virus with engineered capsid
|
|
CN113966236A
(zh)
|
2019-04-03 |
2022-01-21 |
再生生物股份有限公司 |
眼睛病状的基因疗法
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
EP4310495A3
(en)
|
2019-04-11 |
2024-04-24 |
REGENXBIO Inc. |
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
|
|
JP7630443B2
(ja)
|
2019-04-19 |
2025-02-17 |
レジェンクスバイオ インコーポレーテッド |
アデノ随伴ウイルスベクター製剤及び方法
|
|
BR112021021156A2
(pt)
|
2019-04-24 |
2022-02-08 |
Regenxbio Inc |
Terapêuticos anticorpos totalmente humanos pós-tradução modificados
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
PH12021552608A1
(en)
*
|
2019-04-29 |
2022-06-20 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same
|
|
WO2020227166A1
(en)
|
2019-05-03 |
2020-11-12 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
AR118928A1
(es)
|
2019-05-14 |
2021-11-10 |
Biomarin Pharm Inc |
Métodos de redosificación de vectores de terapia génica
|
|
CA3135271A1
(en)
|
2019-05-28 |
2020-12-03 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
CN114207120A
(zh)
|
2019-05-30 |
2022-03-18 |
坚固生物科技公司 |
重组疱疹病毒载体
|
|
US20230241248A1
(en)
|
2019-06-27 |
2023-08-03 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
EP3994253A1
(en)
|
2019-07-02 |
2022-05-11 |
M6P Therapeutics (Switzerland) LLC |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
US20220282276A1
(en)
|
2019-07-11 |
2022-09-08 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated virus
|
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
JP2022544015A
(ja)
|
2019-07-23 |
2022-10-17 |
ユニバーシティ オブ ロチェスター |
ＣＲＩＳＰＲ－Ｃａｓでの標的化されたＲＮＡ切断
|
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
US20220396806A1
(en)
|
2019-07-26 |
2022-12-15 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
TW202112797A
(zh)
|
2019-08-16 |
2021-04-01 |
日商摩大力斯醫療公司 |
經由靶向lama1基因治療肌肉萎縮症的方法
|
|
US20220288235A1
(en)
*
|
2019-08-20 |
2022-09-15 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
|
WO2021041373A1
(en)
|
2019-08-26 |
2021-03-04 |
Regenxbio Inc. |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
EP4021934A4
(en)
|
2019-08-30 |
2024-02-14 |
The Regents of the University of California |
Gene fragment overexpression screening methodologies, and uses thereof
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
EP4028532A1
(en)
|
2019-09-13 |
2022-07-20 |
Rutgers, the State University of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CN114521143B
(zh)
|
2019-09-19 |
2025-03-14 |
吉尼松公司 |
减轻fkrp心脏毒性的基因治疗表达系统
|
|
JP7620988B2
(ja)
|
2019-09-20 |
2025-01-24 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
CN114728049A
(zh)
|
2019-10-07 |
2022-07-08 |
再生生物股份有限公司 |
腺相关病毒载体药物组合物和方法
|
|
US20220403438A1
(en)
|
2019-10-08 |
2022-12-22 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
|
JP2022552260A
(ja)
|
2019-10-08 |
2022-12-15 |
エクスハウラ リミテッド |
眼治療のための組成物および方法
|
|
EP4450514A3
(en)
|
2019-10-14 |
2025-04-09 |
Duke University |
Compositions comprising novel prokaryotic sodium channels and associated methods
|
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
US20220396808A1
(en)
*
|
2019-11-08 |
2022-12-15 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
EP4055034A4
(en)
*
|
2019-11-08 |
2024-05-29 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
KR20220107222A
(ko)
*
|
2019-11-28 |
2022-08-02 |
리젠엑스바이오 인크. |
마이크로디스트로핀 유전자 치료 작제물 및 이의 용도
|
|
CN114981442A
(zh)
*
|
2019-12-04 |
2022-08-30 |
桑格摩生物治疗股份有限公司 |
用于生产重组aav的新颖组合物及方法
|
|
TW202129002A
(zh)
|
2019-12-09 |
2021-08-01 |
英商Ｕｃｌ商業有限責任公司 |
用於myh7關聯之心肌病之基因療法組合物及治療
|
|
EP4072595A1
(en)
|
2019-12-10 |
2022-10-19 |
Takeda Pharmaceutical Company Limited |
Adeno associated virus vectors for the treatment of hunter disease
|
|
AU2020416291A1
(en)
|
2019-12-31 |
2022-07-21 |
Swanbio Therapeutics Limited |
Improved AAV-ABCD1 constructs and use for treatment or prevention of adrenoleukodystrophy (ALD) and/or adrenomyeloneuropathy (AMN)
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
JP2023511382A
(ja)
|
2020-01-22 |
2023-03-17 |
レジェンクスバイオ インコーポレーテッド |
完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療
|
|
EP4097238A1
(en)
|
2020-01-29 |
2022-12-07 |
REGENXBIO Inc. |
Treatment of mucopolysaccharidosis iva
|
|
TW202142695A
(zh)
|
2020-01-29 |
2021-11-16 |
美商銳進科斯生物股份有限公司 |
用人類神經或神經膠質細胞產生之重組人類艾杜糖醛酸—２—硫酸酯酶（ｉｄｓ）對ｉｉ型黏多糖病之治療
|
|
WO2021155337A1
(en)
|
2020-02-02 |
2021-08-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
|
KR20220141829A
(ko)
|
2020-02-07 |
2022-10-20 |
유니버시티 오브 로체스터 |
리보자임-매개 rna 조립 및 발현
|
|
JP2023513211A
(ja)
|
2020-02-07 |
2023-03-30 |
ユニバーシティ オブ ロチェスター |
タンパク質合成を増強するためのＣＲＩＳＰＲ－Ｃａｓ１３による標的ＲＮＡ翻訳
|
|
IL294781A
(en)
|
2020-02-14 |
2022-09-01 |
Ultragenyx Pharmaceutical Inc |
Gene therapy for treating cdkl5 deficiency disorder
|
|
WO2021170784A1
(en)
|
2020-02-28 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
|
CA3173567A1
(en)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
|
MX2022010936A
(es)
|
2020-03-05 |
2022-11-16 |
Neotx Therapeutics Ltd |
³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.
|
|
EP4118098A4
(en)
|
2020-03-11 |
2024-06-12 |
The Trustees of The University of Pennsylvania |
METHOD AND COMPOSITION FOR GENE DELIVERY USING AN MANIPULATED VIRUS PARTICLE
|
|
EP4121544A1
(en)
*
|
2020-03-19 |
2023-01-25 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
WO2021195519A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
|
JP2023519344A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
ＣＲＩＳＰＲ－Ｃａｓ１３ ｃｒＲＮＡアレイ
|
|
IL296732A
(en)
|
2020-03-27 |
2022-11-01 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
EP4127189A1
(en)
|
2020-03-31 |
2023-02-08 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
US20230226223A1
(en)
|
2020-04-10 |
2023-07-20 |
Sola Biosciences Llc |
Compositions and Methods for the Treatment of Protein Aggregation Disorders
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
US20230220014A1
(en)
*
|
2020-04-20 |
2023-07-13 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
CN116368221A
(zh)
|
2020-04-22 |
2023-06-30 |
因达普塔治疗公司 |
自然杀伤(nk)细胞组合物及其生成方法
|
|
KR20230025659A
(ko)
|
2020-04-28 |
2023-02-22 |
솔라 바이오사이언시즈 엘엘씨 |
Tdp-43 단백질병증의 치료를 위한 조성물 및 방법
|
|
MX2022013963A
(es)
|
2020-05-05 |
2023-02-22 |
Univ Duke |
Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
|
|
TW202208622A
(zh)
|
2020-05-12 |
2022-03-01 |
賓州大學委員會 |
用於治療克拉培氏病之組成物
|
|
AU2021270447A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions for DRG-specific reduction of transgene expression
|
|
JP2023526047A
(ja)
|
2020-05-13 |
2023-06-20 |
アコーオス インコーポレイテッド |
Ｓｌｃ２６ａ４関連難聴を治療するための組成物及び方法
|
|
US20230203102A1
(en)
|
2020-05-13 |
2023-06-29 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
TW202208406A
(zh)
|
2020-05-13 |
2022-03-01 |
美商阿科奧斯公司 |
用於治療ｋｃｎｑ４相關性聽力損失之組成物及方法
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
WO2021248038A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
|
CA3183153A1
(en)
|
2020-06-17 |
2021-12-23 |
Christian HINDERER |
Compositions and methods for treatment of gene therapy patients
|
|
WO2021255245A2
(en)
|
2020-06-19 |
2021-12-23 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
|
CA3187635A1
(en)
*
|
2020-07-03 |
2022-01-06 |
Genethon |
Method for engineering novel hybrid aav capsids through hypervariable regions swapping
|
|
KR20230035584A
(ko)
*
|
2020-07-07 |
2023-03-14 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Dwarf 개방 판독 프레임을 위한 아데노-관련 바이러스 벡터
|
|
US20230277686A1
(en)
|
2020-07-10 |
2023-09-07 |
Genethon |
A novel muscle-specific promoter
|
|
IL299771A
(en)
|
2020-07-10 |
2023-03-01 |
Inst Nat Sante Rech Med |
Methods and compounds for the treatment of epilepsy
|
|
TW202216244A
(zh)
|
2020-07-13 |
2022-05-01 |
賓州大學委員會 |
有用於治療夏馬杜三氏病之組成物
|
|
US20230348871A1
(en)
|
2020-07-15 |
2023-11-02 |
University Of Rochester |
Targeted RNA cleavage with dCas13-RNase Fusion Proteins
|
|
CA3190309A1
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
CN116121275B
(zh)
*
|
2020-07-29 |
2024-11-29 |
北京三诺佳邑生物技术有限责任公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
US20230295656A1
(en)
|
2020-08-06 |
2023-09-21 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4196494A1
(en)
|
2020-08-17 |
2023-06-21 |
Massachusetts Institute of Technology |
Shank3 gene therapy approaches
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
MX2023002293A
(es)
|
2020-08-24 |
2023-05-19 |
Univ Pennsylvania |
Vectores virales que codifican fusiones de agonistas del receptor de glp-1 y usos de estos en el tratamiento de enfermedades metabólica.
|
|
MX2023002364A
(es)
|
2020-08-26 |
2023-05-22 |
Univ Pennsylvania |
Virus adenoasociado recombinante para el tratamiento de la neurodegeneración iniciada en adultos asociada a grn.
|
|
BR112023003972A2
(pt)
|
2020-09-04 |
2023-04-18 |
Univ Kobe Nat Univ Corp |
Complexos de um módulo de reconhecimento de sequência de ácido nucleico ligado a uma desaminase e de um fragmento amino-terminal de um módulo de reconhecimento de sequência de ácido nucleico, uma desaminase e um fragmento carboxi-terminal de um módulo de reconhecimento de sequência de ácido nucleico ligado ao mesmo, ácido nucleico, vetor, e, método para alterar um sítio alvo de um ácido desoxirribonucleico de fita dupla de uma célula
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
AU2021358964A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
WO2022076549A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
IL301647A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
JP2023544803A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
Ｃｌｎ２疾患の眼症状に対する遺伝子療法
|
|
US20230414788A1
(en)
|
2020-10-07 |
2023-12-28 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
|
KR20230118075A
(ko)
|
2020-10-09 |
2023-08-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
파브리병 치료를 위한 조성물 및 방법
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
TW202229315A
(zh)
|
2020-10-18 |
2022-08-01 |
賓州大學委員會 |
改良的腺相關病毒(aav)載體及其用途
|
|
CN116528892A
(zh)
|
2020-10-28 |
2023-08-01 |
再生生物股份有限公司 |
用于眼部适应症的载体化抗TNF-α抗体
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
EP4236974A2
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
|
WO2022094461A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
|
IL302608A
(en)
|
2020-11-03 |
2023-07-01 |
Pfizer |
Methods for purification of aav vectors by anion exchange chromatography
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
EP4256065A2
(en)
|
2020-12-01 |
2023-10-11 |
The Trustees of The University of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
|
CA3200192A1
(en)
|
2020-12-01 |
2022-06-09 |
Justin PERCIVAL |
Compositions and uses thereof for treatment of angelman syndrome
|
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
|
CA3201743A1
(en)
|
2020-12-16 |
2022-06-23 |
Robert STADELMAN |
Method of producing a recombinant adeno-associated virus particle
|
|
IL303959A
(en)
|
2020-12-23 |
2023-08-01 |
Pfizer |
Methods for purification of aav vectors by affinity chromatography
|
|
EP4271419A1
(en)
|
2020-12-29 |
2023-11-08 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
JP2024503895A
(ja)
|
2021-01-21 |
2024-01-29 |
リジェネクスバイオ インコーポレイテッド |
組換えポリペプチド及びウイルスの生成の改善
|
|
KR20230149299A
(ko)
*
|
2021-01-25 |
2023-10-26 |
트라메스 바이오 인코포레이티드 |
초점 간질 및 신경병성 통증 치료를 위한 아데노-연관 바이러스 캡시드 및 조작된 리간드 개폐 이온 채널
|
|
EP4284335A1
(en)
|
2021-02-01 |
2023-12-06 |
RegenxBio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US11926842B2
(en)
*
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
|
JP2024506296A
(ja)
|
2021-02-05 |
2024-02-13 |
メイズ セラピューティクス， インコーポレイテッド |
スタッファーポリヌクレオチド配列を含むベクター
|
|
AU2022218706A1
(en)
*
|
2021-02-09 |
2023-09-28 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
CA3209611A1
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
JP2024511024A
(ja)
|
2021-03-19 |
2024-03-12 |
アドリーナス セラピューティクス， インコーポレイテッド |
２１－ヒドロキシラーゼ欠損症の遺伝子治療
|
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
WO2022216749A1
(en)
|
2021-04-05 |
2022-10-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
US20240191258A1
(en)
|
2021-04-12 |
2024-06-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
|
CA3216146A1
(en)
|
2021-04-23 |
2022-10-27 |
Douglas Anderson |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
|
EP4334334A1
(en)
|
2021-04-23 |
2024-03-13 |
The Trustees of The University of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
WO2022229807A1
(en)
|
2021-04-26 |
2022-11-03 |
Pfizer Inc. |
Adeno-associated viral vector capsids with improved tissue tropism
|
|
CA3216744A1
(en)
|
2021-04-26 |
2022-11-03 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
US20240358857A1
(en)
|
2021-05-11 |
2024-10-31 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
JP2024520815A
(ja)
*
|
2021-06-08 |
2024-05-24 |
エヌエフ２ セラピューティクス， インコーポレイテッド |
神経線維腫性障害を処置するための組成物および方法
|
|
EP4355888A4
(en)
*
|
2021-06-18 |
2025-07-02 |
Dyno Therapeutics Inc |
CAPSID VARIANTS AND METHODS OF USE THEREOF
|
|
US20240271160A1
(en)
|
2021-06-22 |
2024-08-15 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
US20240287493A1
(en)
*
|
2021-06-24 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
|
EP4362957A1
(en)
|
2021-07-01 |
2024-05-08 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
AU2022307365A1
(en)
|
2021-07-08 |
2024-02-01 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
CN118076744A
(zh)
*
|
2021-07-23 |
2024-05-24 |
杜克大学 |
腺相关病毒组合物及其使用方法
|
|
IL310515A
(en)
|
2021-07-30 |
2024-03-01 |
Toru Miyazaki |
Therapeutic agent for ischemic disease
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
TW202338095A
(zh)
*
|
2021-08-25 |
2023-10-01 |
美商北海康成製藥有限公司 |
包含肝臟向性衣殼蛋白質及酸α－葡萄糖苷酶（ＧＡＡ）之ＡＡＶ顆粒及其用於治療龐貝氏病（ＰＯＭＰＥ ＤＩＳＥＡＳＥ）之用途
|
|
KR20240073025A
(ko)
*
|
2021-08-25 |
2024-05-24 |
캔브리지 파마슈티컬스, 인크. |
간-향성 캡시드 단백질 및 알파-갈락토시다제를 포함하는 aav 입자 및 파브리 질환을 치료하기 위한 이의 용도
|
|
KR20240107201A
(ko)
|
2021-08-31 |
2024-07-08 |
스카우트 바이오, 인코포레이티드 |
항원-결합 분자 및 이의 용도
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
US20230151372A1
(en)
*
|
2021-10-07 |
2023-05-18 |
Academia Sinica |
Composition and Method of Treatment for Heart Protection and Regeneration
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
MX2024004217A
(es)
|
2021-10-08 |
2024-06-26 |
Dyno Therapeutics Inc |
Variantes de cápside y métodos de uso de estas.
|
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
|
EP4415746A1
(en)
|
2021-10-12 |
2024-08-21 |
Bridgebio Gene Therapy LLC |
Methods and compositions for treating leukodystrophies
|
|
US20230241118A1
(en)
|
2021-10-20 |
2023-08-03 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss
|
|
EP4423285A1
(en)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
CA3236365A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
KR20240113624A
(ko)
|
2021-11-02 |
2024-07-22 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드 변이체 및 이의 용도
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4433169A1
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2023093905A1
(zh)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
WO2023114897A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
CA3248878A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
GENE THERAPY COMPOSITION AND TREATMENT OF DYSTROPHIN-RELATED CARDIOMYOPATHY
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
IL314434A
(en)
|
2022-01-25 |
2024-09-01 |
Univ Pennsylvania |
AAV capsids for enhanced cardiac transduction and liver targeting neutralization
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
AU2023215253A1
(en)
|
2022-02-02 |
2024-09-19 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
AU2023217698A1
(en)
|
2022-02-08 |
2024-07-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
KR20240155390A
(ko)
|
2022-02-17 |
2024-10-28 |
사나 바이오테크놀로지, 인크. |
조작된 cd47 단백질 및 이의 용도
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4482970A1
(en)
|
2022-02-23 |
2025-01-01 |
Massachusetts Institute of Technology |
Methods for upregulating shank3 expression
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
EP4493226A1
(en)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modified muscle-specific promoters
|
|
EP4499154A1
(en)
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
|
AU2023250660A1
(en)
|
2022-04-06 |
2024-10-24 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
|
|
EP4504258A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of the University of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
CA3247109A1
(en)
|
2022-04-06 |
2023-10-12 |
Univ Pennsylvania |
Compositions and treatment methods for metastatic breast cancer that is human epidermal growth factor receptor 2 positive and other cancers
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
JP2025513835A
(ja)
|
2022-04-11 |
2025-04-30 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック |
化学修飾型アデノ随伴ウイルス
|
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
EP4518972A2
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
US20250288697A1
(en)
|
2022-05-03 |
2025-09-18 |
Regenxbio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
IL317433A
(en)
*
|
2022-05-24 |
2025-02-01 |
Kate Therapeutics Inc |
Compounds for the treatment of XLMTM
|
|
CA3257081A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics Inc |
VAA CAPSIDE VARIANTS AND THEIR USES
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics Inc |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
EP4577663A2
(en)
|
2022-08-24 |
2025-07-02 |
RegenxBio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
CN119768188A
(zh)
|
2022-08-25 |
2025-04-04 |
武田药品工业株式会社 |
用于治疗法布里病的组合物
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
|
UY40443A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía con vectores de genoterapia con aav
|
|
IL319873A
(en)
|
2022-09-30 |
2025-05-01 |
Regenxbio Inc |
Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
|
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
CN121127599A
(zh)
|
2022-12-17 |
2025-12-12 |
宾夕法尼亚州大学信托人 |
具有心肌和骨骼肌特异性靶向基序的重组aav突变载体及含有其的组合物
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
CN120752339A
(zh)
|
2023-01-06 |
2025-10-03 |
国家医疗保健研究所 |
静脉内施用用于治疗疼痛的反义寡核苷酸
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
EP4649160A1
(en)
|
2023-01-12 |
2025-11-19 |
Nantes Université |
Chemically-modified adeno-associated virus
|
|
WO2024163979A2
(en)
*
|
2023-02-02 |
2024-08-08 |
Codexis, Inc. |
Engineered aav polypeptides
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4658294A2
(en)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Competitive replacement of glial cells
|
|
AU2024221161A1
(en)
|
2023-02-17 |
2025-08-28 |
Biogen Ma Inc. |
Rgd-containing peptides for delivering payloads
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
KR20250158036A
(ko)
|
2023-03-17 |
2025-11-05 |
유니버시티 오브 로체스터 |
리보자임-매개 rna 조립 및 발현
|
|
WO2024206226A1
(en)
*
|
2023-03-25 |
2024-10-03 |
Duke University |
Compositions comprising kidney-tropic aavs and methods of use thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024220463A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav5 capsid with non-canonical amino acid incorporation and uses thereof
|
|
WO2024220389A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav2 variants and uses thereof
|
|
AU2024258047A1
(en)
|
2023-04-18 |
2025-10-23 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
WO2024218190A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
TW202449167A
(zh)
|
2023-04-26 |
2024-12-16 |
美商航海家醫療公司 |
用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024229389A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2024229125A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
CN121079310A
(zh)
|
2023-05-03 |
2025-12-05 |
沃雅戈治疗公司 |
用于治疗与cdkl5缺乏相关的病症的组合物及方法
|
|
AU2024266519A1
(en)
|
2023-05-03 |
2025-12-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2024229425A1
(en)
|
2023-05-04 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025017168A1
(en)
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|
|
WO2025017169A1
(en)
|
2023-07-20 |
2025-01-23 |
Genethon |
Novel mididystrophins
|
|
WO2025035143A1
(en)
|
2023-08-10 |
2025-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025042711A1
(en)
|
2023-08-18 |
2025-02-27 |
Eli Lilly And Company |
Engineered transferrin receptor binding peptides as well as methods of making and using the same
|
|
WO2025072604A1
(en)
|
2023-09-28 |
2025-04-03 |
University Of Rochester |
Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025080780A1
(en)
|
2023-10-10 |
2025-04-17 |
University Of Rochester |
Delivery and expression of prime editing crispr systems
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025096967A1
(en)
|
2023-11-02 |
2025-05-08 |
Biogen Ma Inc. |
Redirection of aav capsids for central nervous system targeting
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025171001A1
(en)
|
2024-02-06 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for improved production of aav viral vectors
|
|
WO2025188625A1
(en)
|
2024-03-03 |
2025-09-12 |
Passage Bio, Inc. |
Recombinant adeno-associated virus for treatment of neurodegenerative disorders
|
|
WO2025188755A1
(en)
|
2024-03-04 |
2025-09-12 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025207948A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids for targeting human transferrin receptor
|
|
WO2025207932A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids comprising anti-transferrin antibody domains
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025242657A1
(en)
|
2024-05-21 |
2025-11-27 |
Shape Biopharmaceuticals Ag |
Lipopeptide building blocks and aggregates
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|